Literature DB >> 28740534

Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider?

Steven De Keukeleire1, Kristoff Muylle2, Georgios Tsoumalis3, Stefan Vermeulen4, Dirk Vogelaers5.   

Abstract

Primary hyperparathyroidism (PHPT) is probably the most common endocrine disorder of the parathyroid glands, causing hypercalcemia. It is diagnosed often in persons with elevated serum calcium levels. However, hematological manifestations, such as thrombocytopenia are less known. In this case we describe the possible association of PHPT with reversible thrombocytopenia after parathyroidectomy. This hematological abnormality can be included in the spectrum of possible causes, including seemingly non-specific symptoms, in the decision tree towards surgical assessment.

Entities:  

Keywords:  parathyroidectomy; primary hyperparathyroidism; thrombocytopenia

Year:  2017        PMID: 28740534      PMCID: PMC5505723          DOI: 10.11138/ccmbm/2017.14.1.097

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  12 in total

Review 1.  Clinical practice. Primary hyperparathyroidism.

Authors:  Claudio Marcocci; Filomena Cetani
Journal:  N Engl J Med       Date:  2011-12-22       Impact factor: 91.245

2.  Anemia and thrombocytopenia improves after curative parathyroidectomy in a patient of primary hyperparathyroidism (PHPT).

Authors:  Sanjay Kumar Bhadada; Subbiah Sridhar; Jasmina Ahluwalia; Anil Bhansali; Pankaj Malhotra; Arunanshu Behera; Bhagwant Rai Mittal
Journal:  J Clin Endocrinol Metab       Date:  2012-03-14       Impact factor: 5.958

3.  Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.

Authors:  D S Rao; M S Shih; R Mohini
Journal:  N Engl J Med       Date:  1993-01-21       Impact factor: 91.245

4.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

5.  Anaemia and marrow fibrosis in patients with primary hyperparathyroidism before and after curative parathyroidectomy.

Authors:  Sanjay K Bhadada; Anil Bhansali; Jasmina Ahluwalia; G V Chanukya; Arunanshu Behera; Pinaki Dutta
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-22       Impact factor: 3.478

6.  Myelofibrosis secondary to renal osteodystrophy.

Authors:  S Nomura; Y Ogawa; G Osawa; M Katagiri; T Harada; H Nagahana
Journal:  Nephron       Date:  1996       Impact factor: 2.847

Review 7.  Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  R Eastell; A Arnold; M L Brandi; E M Brown; P D'Amour; D A Hanley; D Sudhaker Rao; M R Rubin; D Goltzman; S J Silverberg; S J Marx; M Peacock; L Mosekilde; R Bouillon; E M Lewiecki
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

8.  Current status and treatment of primary hyperparathyroidism.

Authors:  Dina M Elaraj; Orlo H Clark
Journal:  Perm J       Date:  2008

9.  Primary hyperparathyroidism: an overview.

Authors:  Jessica Mackenzie-Feder; Sandra Sirrs; Donald Anderson; Jibran Sharif; Aneal Khan
Journal:  Int J Endocrinol       Date:  2011-06-02       Impact factor: 3.257

10.  The resolution of anemia after curative parathyroidectomy is sustained even after a decade.

Authors:  Sanjay Kumar Bhadada; Ashutosh Kumar Arya; Girish Parthan; Priyanka Singh
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct
View more
  2 in total

Review 1.  Calcium regulation of stem cells.

Authors:  Hans-Willem Snoeck
Journal:  EMBO Rep       Date:  2020-05-17       Impact factor: 8.807

2.  Haematological manifestations in primary hyperparathyroidism.

Authors:  Seher Kır; Cafer Polat
Journal:  Indian J Med Res       Date:  2022-01       Impact factor: 5.274

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.